MaxCyte Announces Pricing of Upsized Offering and Approval to List on the Nasdaq Global Select Market
This announcement contains inside information
News provided by
Share this article
Share this article
GAITHERSBURG, Md., July 29, 2021 /PRNewswire/ MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the pricing of its upsized offering of 13,500,000 shares of common stock at an initial offering price of US$13.00 per share (the
Offering ).
Highlights
Anticipated gross proceeds of approximately US$175,500,000 (or US$201,825,000 if the underwriters exercise their option to purchase additional shares of common stock in full), before deducting underwriting discounts and commissions and estimated offering expenses payable by MaxCyte
Logitech Files Quarterly Report on Form 10-Q
LAUSANNE, Switzerland & NEWARK, Calif.–(BUSINESS WIRE)–SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR
Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that on July 29, 2021, it filed with the U.S. Securities and Exchange Commission (SEC) its Quarterly Report on Form 10-Q for the first quarter of Fiscal Year 2022. The filing is available on the SEC’s website at www.sec.gov and Logitech’s website at http://ir.logitech.com.
About Logitech
Logitech helps all people pursue their passions by designing experiences so everyone can create, achieve, and enjoy more. Logitech designs and creates products that bring people together through computing, gaming, video, streaming and creating, and music. Brands of Logitech include Logitech, Logitech G, ASTRO Gaming, Streamlabs, Blue Microphones, Ultimate Ears and Jaybird. Founded in 1981, and headquartered in Lausanne, Switzerland, Logitech International is a Sw
Omega Therapeutics Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
CAMBRIDGE, Mass, July 29, 2021 /PRNewswire/ Omega Therapeutics, Inc. (Nasdaq: OMGA) ( Omega ), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Omega. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Omega, are expected to be approximately $125.8 million, excluding any exercise of the underwriters option to purchase additional shares. Omega s common stock is expected to begin trading on the Nasdaq
Omega Therapeutics Prices 7.4 Mln Shares Of IPO At $17.00 Per Share
WASHINGTON (dpa-AFX) - Omega Therapeutics, Inc. (OMGA), a development-stage biotechnology company specializing in epigenetics on Thursday announced $17 per share as the price of its Initial Public Offering (IPO) of 7,400,000 shares.
Proceeds from the offering before deducting expenses etc. payable by Omega and excluding underwriters option are expected to be approximately $125.8 million.
Shares of the company, which uses its OMEGA Epigenomic Programming platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol OMGA on July 30, 2021.
Southern States Bancshares Announces Launch of Initial Public Offering apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.